诊断学理论与实践››2016,Vol. 15››Issue (06): 561-566.doi:10.16150/j.1671-2870.2016.06.004
肖超, 常春康
收稿日期:2016-10-17出版日期:2016-12-25发布日期:2022-07-27通讯作者:常春康 E-mail: changchunkang@sina.com
Received:2016-10-17Online:2016-12-25Published:2022-07-27| [1] Steensma DP, Bennett JM.The myelodysplastic syndromes: diagnosis and treatment[J]. Mayo Clin Proc,2006,81(1):104-130. [2] Santini V, Girelli D, Sanna A, et al.Hepcidin levels and their determinants in different types of myelodysplastic syndromes[J]. PLoS One,2011,6(8):e23109. [3] Ambaglio I, Malcovati L, Papaemmanuil E, et al.Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1[J]. Haematologica,2013,98(3):420-423. [4] Porter JB, de Witte T, Cappellini MD, et al. New insights into transfusion-related iron toxicity: Implications for the oncologist[J]. Crit Rev Oncol Hematol,2016,99:261-271. [5] Chung YJ, Robert C, Gough SM, et al.Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome[J]. Leuk Res,2014,38(1):95-102. [6] Kikuchi S, Kobune M, Iyama S, et al.Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox[J]. Free Radic Biol Med,2012, 53(4):643-648. [7] Gattermann N, Finelli C, Della Porta M, et al.Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes[J]. Haematologica,2012,97(9):1364-1371. [8] Goldberg SL, Chen E, Corral M, et al.Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries[J]. J Clin Oncol,2010,28(17):2847-2852. [9] Greenberg PL, Attar E, Bennett JM, et al.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes[J]. J Natl Compr Canc Netw,2011,9(1):30-56. [10] Armand P, Kim HT, Rhodes J, et al.Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation[J]. Biol Blood Marrow Transplant,2011,17(6):852-860. [11] Carpenter JP, He T, Kirk P, et al.On T2* magnetic resonance and cardiac iron[J]. Circulation,2011,123(14):1519-1528. [12] Zipperer E, Post JG, Herkert M, et al.Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome[J]. Ann Hematol,2013,92(12):1617-1623. [13] Roth M, Will B, Simkin G, et al.Eltrombopag inhibits the proliferation of leukemia cells [14] Hartmann J, Braulke F, Sinzig U, et al.Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes[J]. Leuk Res,2013,37(3):327-332. |
| [1] | 王柔嘉, 常春康.调节性T细胞在骨髓增生异常综合征危险分层中的研究进展[J]. 诊断学理论与实践, 2021, 20(02): 221-224. |
| [2] | 叶成林, 姚永华, 陈真, 贾麟.骨髓活检塑胶包埋在以单纯血小板减少为表现的骨髓增生异常综合征诊断中的应用价值[J]. 诊断学理论与实践, 2020, 19(02): 177-181. |
| [3] | 吴凌云, 常春康.骨髓增生异常综合征的诊治最新进展[J]. 诊断学理论与实践, 2019, 18(06): 623-629. |
| [4] | 杜云志, 冯菁华, 常春康.二代测序技术在骨髓增生异常综合征临床诊断和治疗决策中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 685-671. |
| [5] | 宋丹丹, 常春康, 郭娟, 许峰, 赵佑山, 吴凌云.骨髓增生异常综合征患者骨髓巨噬细胞百分比异常及其意义[J]. 诊断学理论与实践, 2018, 17(04): 439-443. |
| [6] | 师蕾, 常春康.间充质干细胞在骨髓增生异常综合征发病机制中的研究进展[J]. 诊断学理论与实践, 2018, 17(01): 123-126. |
| [7] | 肖志坚.骨髓增生异常综合征的诊断[J]. 诊断学理论与实践, 2016, 15(06): 545-549. |
| [8] | 赵智刚, 王金焕.骨髓微环境调控骨髓增生异常综合征的作用及相关机制[J]. 诊断学理论与实践, 2016, 15(06): 550-555. |
| [9] | 宋陆茜, 常春康.二代测序技术在骨髓增生异常综合征诊治中的临床应用[J]. 诊断学理论与实践, 2016, 15(06): 556-560. |
| [10] | 杨丽艳, 王化泉.血小板生成素受体激动剂的作用机制及其在骨髓增生异常综合征治疗中的应用[J]. 诊断学理论与实践, 2016, 15(06): 567-572. |
| [11] | 任艳玲, 佟红艳.骨髓增生异常综合征常用药物治疗的机制[J]. 诊断学理论与实践, 2016, 15(06): 573-577. |
| [12] | 常春康,.骨髓增生异常综合征WHO(2016)分型的修正[J]. 诊断学理论与实践, 2016, 15(03): 222-225. |
| [13] | 常春康,.骨髓增生异常综合征分类的演变:从FAB到WHO及将来[J]. 诊断学理论与实践, 2014, 13(01): 101-106. |
| [14] | 贺琪, 常春康,.骨髓增生异常综合征分子发病机制的新进展[J]. 诊断学理论与实践, 2014, 13(01): 90-94. |
| [15] | 佟红艳,.骨髓增生异常综合征分子机制新进展的认识[J]. 诊断学理论与实践, 2013, 12(01): 9-15. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
